CN111542744B

CN111542744B - Blood analyzer, blood analysis method, and computer-readable storage medium

Info

Publication number: CN111542744B
Application number: CN202080001015.3A
Authority: CN
Inventors: 祁欢; 苟理尧; 潘世耀; 肖建萍; 王官振; 叶波; 叶燚
Original assignee: Shenzhen Mindray Bio Medical Electronics Co Ltd
Current assignee: Shenzhen Mindray Bio Medical Electronics Co Ltd
Priority date: 2020-03-10
Filing date: 2020-03-10
Publication date: 2024-03-15
Anticipated expiration: 2040-03-10
Also published as: WO2021179177A1; CN111542744A

Abstract

The embodiment of the invention discloses a blood analyzer, a blood analysis method and a readable storage medium for prompting a novel coronavirus infection sample according to blood routine parameters. The blood analyzer includes: the sampling device is used for sucking a blood sample to be tested; sample preparation means for preparing a sample fluid to be tested from a blood sample to be tested and a treatment reagent; the detection device is used for detecting the sample liquid to be detected to obtain blood routine parameters; display means for displaying information related to blood routine parameters; and the control device is configured to acquire analysis parameters related to the novel coronavirus infection from blood routine parameters of the blood sample to be tested, and when the analysis parameters meet preset conditions, the control display device is controlled to display alarm information related to the novel coronavirus infection. The implementation of the invention can realize low cost and rapid output of the novel coronavirus infection related information and alarm.

Description

Blood analyzer, blood analysis method, and computer-readable storage medium

Technical Field

The embodiment of the invention relates to the field of blood detection, in particular to a blood analyzer, a blood analysis method and a computer readable storage medium for prompting a novel coronavirus infection sample according to blood routine parameters.

Background

The novel coronavirus belongs to coronaviruses of beta genus, has envelope, and the particles are round or elliptic, often polymorphic, and have diameters of 60-140nm. The gene characteristics of 2019-nCoV are clearly different from SARSr-Cov and MERSr-Cov. The current research shows that the homology of 2019-nCoV and bat SARS-like coronavirus (bat-SL-CoVZC 45) is more than 85%. 2019-nCoV can be found in human respiratory epithelial cells after in vitro isolated culture for about 96 hours, while isolated culture in Vero E6 and Huh-7 cell lines takes about 6 days.

Among the diagnostic criteria for novel coronavirus pneumonia, the need for real-time fluorescent RT-PCR detection or viral gene sequencing is clearly proposed. However, nucleic acid detection and gene sequencing are long, typically one day, and thus may further spread viruses in suspected patients due to the inability to timely diagnose whether the suspected patients are infected with the novel coronavirus pneumonia.

Disclosure of Invention

Therefore, in view of the above circumstances, an object of the embodiments of the present invention is to provide a solution that can prompt a new coronavirus infection sample based on blood routine parameters quickly and at low cost, in which the new coronavirus infection sample can be pre-warned by using existing blood routine parameters of a blood cell analyzer, and assist medical staff in quickly judging whether a suspected patient is likely to be infected with a new coronavirus, even judging the infection degree, so that medical staff can make a quick response in advance, preventing further virus diffusion. In addition, the solution does not need extra testing cost, and the early warning of a novel coronavirus infection sample can be realized while the conventional blood detection is carried out by utilizing the existing hemocytometer.

In a first aspect, the present invention provides a blood analyzer for prompting a novel coronavirus infection sample according to blood routine parameters, the blood analyzer comprising: a sampling device having a pipette with a pipette nozzle and having a driving section for driving the pipette to quantitatively aspirate a blood sample to be measured through the pipette nozzle; a sample preparation device having at least one reaction cell for receiving a blood sample to be measured sucked by the sampling device and a reagent supply section for supplying a processing reagent to the at least one reaction cell so that the blood sample to be measured sucked by the sampling device and the processing reagent supplied by the reagent supply section are mixed in the reaction cell to prepare a sample liquid to be measured; a detection device for detecting the sample liquid to be detected prepared by the sample preparation device to obtain blood routine parameters; display means for displaying information related to blood routine parameters; and a control device including a processor and a storage medium storing a computer program, wherein the control is configured to perform the following steps when the computer program is executed by the processor: and acquiring analysis parameters related to the novel coronavirus infection from blood routine parameters of the blood sample to be tested, and controlling the display device to display alarm information related to the novel coronavirus infection when the analysis parameters meet preset conditions.

In a second aspect, the present invention provides a blood analyser operable in a blood routine detection mode or a novel coronavirus infection detection mode, comprising: a sampling device having a pipette with a pipette nozzle and having a driving section for driving the pipette to quantitatively aspirate a blood sample to be measured through the pipette nozzle; a sample preparation device having at least one reaction cell for receiving a blood sample to be measured sucked by the sampling device and a reagent supply section for supplying a processing reagent to the at least one reaction cell so that the blood sample to be measured sucked by the sampling device and the processing reagent supplied by the reagent supply section are mixed in the reaction cell to prepare a sample liquid to be measured; a detection device for detecting the sample liquid to be detected prepared by the sample preparation device to obtain blood routine parameters; display means for displaying information related to blood routine parameters; the mode setting device is used for setting a blood routine mode or a novel coronavirus infection alarm mode; and a control device including a processor and a storage medium storing a computer program, wherein the control device is configured to perform the following steps when the computer program is executed by the processor:

When a novel coronavirus infection detection mode is set by the mode setting means, controlling actions of the sampling means, the sample preparation and the detection means so as to acquire only analysis parameters related to the novel coronavirus infection,

and when the analysis parameters meet preset conditions, controlling the display device to display alarm information related to novel coronavirus infection.

In a third aspect, the present invention provides a blood analysis method for prompting a novel coronavirus infection sample according to blood routine parameters, the method comprising the steps of: providing a blood analyzer; sucking a blood sample to be tested by a sampling and distributing device of the blood analyzer; mixing a portion of the blood sample to be tested with a processing reagent in at least one reaction cell of a blood analyzer to prepare a sample fluid to be tested; detecting blood cells in the sample liquid to be detected in a detection device of a blood analyzer to obtain blood routine parameters; obtaining analysis parameters related to novel coronavirus infection from blood routine parameters of the blood sample to be tested; and when the analysis parameters meet preset conditions, displaying information related to the novel coronavirus infection on a display device of the blood analyzer.

A fourth aspect of the present invention provides a computer readable storage medium for use in a blood analyzer, the computer readable storage medium having a computer program stored thereon, characterized in that the computer program when executed by a processor performs the steps of: obtaining blood routine parameters of a blood sample to be tested, which are measured by a detection device of a blood analyzer; obtaining analysis parameters related to novel coronavirus infection from blood routine parameters of the blood sample to be tested; and when the analysis parameters meet preset conditions, indicating to display information related to the novel coronavirus infection on a display device of the blood analyzer.

Drawings

FIG. 1 is a schematic diagram of a blood analyzer according to an embodiment of the present invention;

FIG. 2 is a schematic diagram of an optical detection portion according to an embodiment of the present invention;

fig. 3 is a schematic diagram of an impedance detecting unit according to an embodiment of the present invention;

FIG. 4 is a schematic diagram of a control device according to an embodiment of the present invention;

FIG. 5 is a schematic representation of a generic ROC curve;

FIG. 6 is a ROC curve for alerting a new coronavirus infection positive sample using single blood routine parameters provided by an embodiment of the present invention;

FIG. 7 is a ROC curve for alerting a positive sample of a new coronavirus infection using a linear combination of two blood conventional parameters provided by an embodiment of the present invention;

FIG. 8 is a ROC curve for alerting a new coronavirus infection positive sample using a nonlinear combination of two blood conventional parameters provided by an embodiment of the present invention;

FIG. 9 is a ROC curve for alerting a new coronavirus infection level using single blood convention parameters provided by an embodiment of the present invention;

FIG. 10 is a ROC curve for alerting a new coronavirus infection level using a linear combination of two blood conventional parameters, according to an embodiment of the present invention;

FIG. 11 is a ROC curve for alerting a new coronavirus infection level using a nonlinear combination of two blood conventional parameters provided by an embodiment of the present invention;

FIG. 12 is a ROC curve for alerting prognosis of a patient with a new coronavirus infection using single blood convention parameters provided by an embodiment of the present invention;

FIG. 13 is a ROC curve for alerting prognosis of a patient with a new coronavirus infection using a linear combination of two blood normal parameters provided by an embodiment of the present invention;

FIG. 14 is a ROC curve for alerting prognosis of a patient with a new coronavirus infection using a linear combination of three blood normal parameters provided by an embodiment of the present invention;

FIG. 15 is a ROC curve for alerting prognosis of a patient with a new coronavirus infection using a nonlinear combination of two blood normal parameters provided by an embodiment of the present invention;

FIG. 16 is a schematic flow chart of a blood analyzer method for alerting a new coronavirus infection using blood routine parameters, as provided by an embodiment of the present invention.

Detailed Description

The following description of the embodiments of the present invention will be made clearly and fully with reference to the accompanying drawings, in which it is evident that the embodiments described are only some, but not all embodiments of the invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.

Throughout the specification, unless specifically indicated otherwise, the terms used herein should be understood as meaning as commonly used in the art. Accordingly, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present specification will control.

It should be noted that, in the embodiments of the present invention, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a method or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such method or apparatus. Without further limitation, the element defined by the phrase "comprising one … …" does not exclude the presence of other related elements (e.g., a step in a method or a unit in an apparatus, where the unit may be a part of a circuit, a part of a processor, a part of a program or software, etc.) in a method or apparatus comprising the element.

It should be noted that, the term "first\second\third" related to the embodiment of the present invention is merely to distinguish similar objects, and does not represent a specific order for the objects, it is to be understood that "first\second\third" may interchange a specific order or sequence where allowed. It is to be understood that the "first\second\third" distinguishing aspects may be interchanged where appropriate to enable embodiments of the invention described herein to be practiced in sequences other than those illustrated or described.

Note that in the present embodiment, ROC is an abbreviation of subject work characteristic Receiver Operating Characteristic. ROC analysis can be used for medical decision evaluation, such as for diagnostic radiology, laboratory medicine, screening for cancer, and diagnosis of psychosis, especially for evaluation of medical imaging diagnostic accuracy. Those skilled in the art understand that the ROC curve mainly relates to the drawing of the ROC curve, calculation of AUC, and selection of the optimal operating point. The ROC curve is calculated for all possible thresholds, each threshold calculating the corresponding TPR (true positive rate, i.e. sensitivity, tpr=true positive number/positive number) and FPR (false positive rate, i.e. 1-specificity, fpr=false positive number/negative number). The multiple pairs of TPR and FPR values are obtained, and then an ROC curve is drawn with the FPR as the x-axis (i.e., abscissa) and the TPR as the y-axis (i.e., ordinate), wherein the minimum value of the abscissa is 0 and the maximum value is 1. A typical ROC curve is shown in fig. 5, where the black dashed line is the ROC curve. ROC curves can characterize the correlation between sensitivity and specificity, thus enabling a dynamic, objective response to the performance of the diagnostic system. AUC is the area enclosed by ROC curve and x-axis (i.e., FPR) (Area Under theCurve), shown as gray area in fig. 5 is AUC, ideal AUC is 1, and minimum is 0.5. The larger the AUC, the better the classification effect of the representative model, and the more accurate the detection of the disease. The optimal working point is selected by determining the optimal combination of TPR and FRP on the selected ROC curve, wherein the points with the maximum TPR and minimum FPR on the curve are the optimal working points, and the optimal working points are selected by the following common methods: positive likelihood ratio method, about index method (Youden index method), method with maximum square sum of sensitivity and specificity, etc.

It is understood that the blood routine test is a method of examining the number, proportion, and morphology of various blood cells in the peripheral blood of a human body by a blood cell analyzer. A Blood Cell analyzer is an instrument capable of detecting cells in Blood, and counting and classifying particles such as White Blood Cells (WBC), red Blood Cells (RBC), platelets (PLT), nucleated Red Blood cells (Nucleated Red Blood Cell, NRBC), and reticulocytes (Ret) in Blood, i.e., a Blood routine test. The blood routine examination has diagnostic reference value, and many patients can make blood routine examination to carry out auxiliary diagnosis when the cause of the disease is unknown. In addition, blood routine examination is a common indicator of observed effects of treatment, medication or withdrawal, continued or discontinued treatment, recurrence of disease, or recovery.

The blood cell analyzer may give the following report parameters and study parameters, as shown in tables 1 and 2 below. In the embodiment of the present invention, the leukocyte parameter is a parameter related to leukocytes obtained by a blood analyzer, the erythrocyte parameter is a parameter related to erythrocytes obtained by a blood analyzer, the platelet parameter is a parameter related to platelets obtained by a blood analyzer, and the hemoglobin parameter is a parameter related to hemoglobin obtained by a blood analyzer.

TABLE 1 blood test report parameter description Table

Is tied up with	Chinese name	English name	Abbreviations (abbreviations)
				White blood cell line (13 items)	White blood cell count	White Blood Cell count	WBC
(same as above)	Basophil number	Basophils number	Bas#
				(same as above)	Basophil percentage	Basophils percentage	Bas%
(same as above)	Neutrophil count	Neutrophils number	Neu#
				(same as above)	Percentage of neutrophils	Neutrophils percentage	Neu%
(same as above)	Eosinophil number	Eosinophils number	Eos#
				(same as above)	Eosinophil percentage	Eosinophils percentage	Eos%
(same as above)	Lymphocyte number	Lymphocytes number	Lym#
				(same as above)	Percentage of lymphocytes	Lymphocytes percentage	Lym%
(same as above)	Monocyte number	Monocytes number	Mon#
				(same as above)	Percentage of monocytes	Monocytes percentage	Mon%
(same as above)	Immature granulocyte count	Immature Granulocyte	IMG#
				(same as above)	Percentage of immature granulocytes	Immature Granulocyte percentage	IMG%
Reticulation red series (9 items)	Percentage of reticulocytes	Reticulocyte percentage	RET%
				(same as above)	Reticulocyte number	Reticulocyte number	RET#
(same as above)	Reticuloendoglobin content expression value	Reticulocyte Hemoglobin Expression	RHE
				(same as above)	Mean hemoglobin content of reticulocytes	Mean Corpuscular Hemoglobin of reticulocytes	MCHr
(same as above)	Mean reticulocyte volume	Mean Corpuscular Volume of reticulocyte	MCVr
				(same as above)	Ratio of immature reticulocytes	Immature reticulocyte fraction	IRF
(same as above)	Low fluorescence intensity reticulocyte ratio	Low fluorescent ratio	LFR
				(same as above)	Medium fluorescence intensity reticulocyte ratio	Middle fluorescent ratio	MFR
(same as above)	High fluorescence intensity reticulocyte ratio	High fluorescent ratio	HFR
				Erythrocyte line (11 items)	Number of red blood cells	Red Blood Cell count	RBC
(same as above)	Hemoglobin concentration	Hemoglobin Concentration	HGB
				(same as above)	Width of hemoglobin concentration distribution	Hemoglobin concentration distribution width	HDW
(same as above)	Average erythrocyte volume	Mean Corpuscular Volume	MCV
				(same as above)	Average erythrocyte hemoglobin content	Mean Corpuscular Hemoglobin	MCH
(same as above)	Mean erythrocyte hemoglobin concentration	Mean Corpuscular Hemoglobin Concentration	MCHC
				(same as above)	Coefficient of variation of distribution width of red blood cells	Red Blood Cell Distribution Width Coefficient of Variation	RDW-CV
(same as above)	Standard deviation of distribution width of red blood cells	Red Blood Cell Distribution Width Standard Deviation	RDW-SD
				(same as above)	Packed red blood cell	Hematocrit	HCT
(same as above)	Number of nucleated red blood cells	Nucleated red blood cell number	NRBC#
				(same as above)	Percentage of nucleated red blood cells	Nucleated red blood cell percentage	NRBC%
Platelet system (9 items)	Platelet count	Platelet count	PLT
				(same as above)	Optical platelet count	Optical Platelet count	PLT-O
(same as above)	Sheath flow impedance channel platelet count	Platelet count- Impedance	PLT-I
				(same as above)	Average platelet volume	Mean Platelet Volume	MPV
(same as above)	Platelet distribution width	Platelet Distribution Width	PDW
				(same as above)	Platelet accumulation	Plateletcrit	PCT
(same as above)	Large platelet ratio	Platelet-large cell ratio	P-LCR
				(same as above)	Number of large platelets	Platelet-large cell count	P-LCC
(same as above)	Immature platelet ratio	Immature Platelet Fraction	IPF

TABLE 2 blood test study parameter description Table

Chinese name	English name	Abbreviations (abbreviations)
			High fluorescence intensity cell number	High fluorescent Cell number	HFC#
High fluorescence intensity cell percentage	High fluorescent Cell percentage	HFC%
			Optical red cell count	Optical Red Blood Cell count	RBC-O
Optical platelet count	Optical Platelet count	PLT-O
			Sheath flow impedance channel platelet count	Platelet count- Impedance	PLT-I
Optical white blood cell count	Optical white blood cell count	WBC-O
			DIFF channel white blood cell count	White blood cell count -DIFF	WBC-D
Total nucleated cell number of DIFF channels	Total nucleated cell counts-DIFF	TNC-D
			Percentage of naive eosinophils	Immature eosinophil percentage	IME%
Number of naive eosinophils	Immature eosinophil number	IME#
			High forward scattered light nucleated red blood cell fraction	High forward scatter NRBC ratio,	H-NR%
Low forward scattered light nucleated red blood cell fraction	Low forward scatter NRBC ratio	L-NR%
			Neutrophil to lymphocyte ratio	Neutrophil-to-lymphocyte ratio	NLR
Platelet to lymphocyte ratio	Platelet-to-lymphocyte ratio	PLR
			WNB channel leukocyte number	White blood cell count-WNB	WBC-N
Total nucleated cell number of WNB channels	Total nucleated cell counts-WNB	TNC-N
			Number of infected erythrocytes	Infected Red Blood Cell count	InR#
Infected red blood cell thousandth	Infected Red Blood Cell permillage	InR‰
			Number of small erythrocytes	Microcyte count	Micro#
Ratio of small red blood cells	Microcyte percentage	Micro%
			Number of big red blood cells	Macrocyte count	Macro#
Ratio of large red blood cells	Macrocyte percentage	Macro%
			Percentage of high pigment red blood cells	Hyperchromic Red Blood Cell Percentage	HYPER%
Percentage of hypopigmented erythrocytes	Hypochromic Red Blood Cell Percentage	HYPO%
			Mean reticulocyte volume	Mean Corpuscular Volume of reticulocyte	MCVr
Absolute number of red cell fragments	RBC Fragment count	FRC#
			Ratio of erythrocyte fragments	RBC Fragment percentage	FRC%
Standard deviation of platelet distribution width	Platelet Distribution Width Standard Deviation	PDW-SD
			Reticulocyte production index	Reticulocyte Production Index	RPI
High fluorescence intensity immature platelet ratio	High fluorescent Immature Platelet Fraction	H-IPF
			Immature platelet count	Immature Platelet Count	IPF#
Average platelet particle size concentration	Mean Platelet Component Concentration	MPC
			Average platelet particle size content	Mean Platelet Matter Content	MPM
Side scatter light intensity for Neu region on DIFF scatter plot	DIFF scattergram, mean neutrophil distribution-side scatter intensity	Neu-X
			Fluorescence intensity of Neu region on DIFF scatter plot	DIFF scattergram, mean neutrophil distribution-side fluorescent light intensity	Neu-Y
Forward scattered light intensity for Neu region on DIFF scatter plot	DIFF scattergram, mean neutrophil distribution- forward scatter intensity	Neu-Z
			Side scatter light intensity for Lym region on DIFF scatter plot	DIFF scattergram, mean lymophocyte distribution- side scatter intensity	Lym - X
Fluorescence intensity of Lym region on DIFF scatter plot	DIFF scattergram, mean lymophocyte distribution-side fluorescent intensity	Lym - Y
			Forward scattered light intensity for Lym region on DIFF scatter plot	DIFF scattergram, mean lymophocyte distribution- forward scatter intensity	Lym - Z
Side scatter light intensity for Mon region on DIFF scatter plot	DIFF scattergram, mean monocyte distribution-s side scatter intensity	Mon - X
			Fluorescence intensity of Mon region on DIFF scatter plot	DIFF scattergram, mean monocyte distribution-side fluorescent light intensity	Mon - Y
Forward scattered light intensity for Mon region on DIFF scatter plot	DIFF scattergram, mean monocyte distribution- forward scatter intensity	Mon -Z
			Erythrocyte count value for bimodal-smaller distribution area of erythrocytes	Dimorphic population, smaller distribution RBC count	SRBC
Erythrocyte count value for bimodal-larger distribution area of erythrocytes	Dimorphic population, larger distribution RBC count	LRBC
			Average erythrocyte volume in bimodal-smaller distribution area of erythrocytes	Dimorphic population, smaller distribution mean corpuscular volume	SMCV
Average erythrocyte volume of bimodal-larger distribution area of erythrocytes	Dimorphic population, larger distribution mean corpuscular volume	LMCV

Since blood routine parameters, such as white blood cell count or lymphocyte count/ratio, of a new coronavirus infection positive blood sample will change specifically compared to a negative sample, the specific change can indicate that the blood sample may be a new coronavirus infection positive sample, and even can indicate the new coronavirus infection degree or development trend. Based on this, the embodiment of the invention provides a solution for prompting a novel coronavirus infection sample according to blood routine parameters. The solution provided by the embodiments of the present invention has the advantages of high speed and low cost, namely, blood routine detection can be completed within 15 minutes from the time of collecting blood routine to the time of completing the test, and the charge of blood routine detection is low, and nucleic acid detection can be completed in one day.

The embodiment of the invention firstly provides a blood analyzer for alarming a new coronavirus infection sample according to blood routine parameters. As shown in fig. 1, the blood analyzer 100 includes at least a sampling device 110, a sample preparation device 120, a detection device 130, a display device 140, and a control device 150.

The sampling device 110 has a pipette (e.g., a sampling needle) with a pipette nozzle and has a driving section for driving the pipette to quantitatively aspirate a blood sample to be measured through the pipette nozzle, for example, the sampling needle is moved to aspirate the blood sample to be measured from a sample container containing the blood sample by driving of the driving section.

The sample preparation device 120 has at least one reaction cell and a reagent supply device (not shown). The at least one reaction cell is used for receiving the blood sample to be measured sucked by the sampling device 110, and the reagent supply device supplies the processing reagent to the at least one reaction cell, so that the blood sample to be measured sucked by the sampling device 110 and the processing reagent supplied by the reagent supply device are mixed in the reaction cell to prepare a sample liquid to be measured. In some embodiments, the reagent supply device comprises a first reagent supply for supplying a leukocyte reagent, e.g. comprising a hemolysing agent capable of lysing erythrocytes in a blood sample and of distinguishing between different leukocyte types, optionally also comprising a fluorescent reagent capable of staining leukocytes. In some embodiments, the reagent supply device comprises a second reagent supply for supplying a red blood cell reagent, such as a diluent. In other embodiments, the reagent supply device comprises a third reagent supply for supplying a hemoglobin reagent, such as a haemolytic agent capable of lysing red blood cells in a blood sample, releasing hemoglobin in the red blood cells and converting the hemoglobin into methemoglobin. In some embodiments, the leukocyte reagent and the hemoglobin reagent are the same hemolysis reagent, i.e., the first reagent supply and the third reagent supply are the same reagent supply.

The detection device 130 is used for detecting the sample liquid to be detected prepared by the sample preparation device 120 to obtain the blood routine parameter.

In some embodiments, the detection device 130 has an optical detection section 131 for detecting a first sample fluid to be tested prepared from a portion of the blood sample to be tested and a leukocyte reagent supplied from the first reagent supply section to obtain a leukocyte parameter, optionally a platelet parameter. As shown in fig. 2, the optical detection section 131 has a light source 1311, a beam shaping member 1312, a flow cell 1313, and a forward scatter detector 1314 arranged in this order on a straight line. On one side of the flow chamber 1313, a dichroic mirror 1316 is arranged at an angle of 45 ° to the straight line. A part of the side light emitted by blood cells in the flow cell 1313 is transmitted through the dichroic mirror 1316 and captured by the fluorescence detector 1315 arranged behind the dichroic mirror 1316 at an angle of 45 ° to the dichroic mirror 1316, while another part of the side light is reflected by the dichroic mirror 1316 and captured by the side scatter detector 1317 arranged in front of the dichroic mirror 1316 at an angle of 45 ° to the dichroic mirror 1316. From the forward scattered light signal captured by the forward scattered light detector 1314, the side scattered light signal captured by the side scattered light detector 1317, and the fluorescent signal captured by the fluorescent light detector 1315, white blood cells in the blood sample may be counted and classified, for example, white blood cells may be classified into at least neutrophils, lymphocytes, and monocytes, and optionally platelet parameters in the blood sample may be further detected, for example, platelet count may be obtained.

In some embodiments, the detection device 130 includes an impedance detection portion 132, where the impedance detection portion 132 is configured to detect a second sample fluid to be detected prepared from a portion of the blood sample to be detected and the red blood cell reagent supplied from the second reagent supply portion to obtain the red blood cell parameter and the platelet parameter. For example, the impedance detecting section 132 is configured as a sheath flow impedance detecting section, and as shown in fig. 3, the sheath flow impedance detecting section 132 includes a flow chamber 1321 having a hole 1322 with an electrode 1323. The sheath flow impedance detecting unit 132 detects the direct current impedance generated when particles in the sample liquid to be measured pass through the hole 1322, and outputs an electric signal reflecting information when the particles pass through the hole. Specifically, the sampling device 110 is driven by its driving device and moves to a reaction cell of the sample preparation device 120 after sucking up the blood sample, and the sucked up blood sample is injected into the reaction cell. The transfer line transfers the sample liquid to be measured after the diluent treatment in the reaction cell to the sheath flow impedance detecting section 132, that is, to the flow chamber 1321. The sheath flow impedance detecting section 132 may be further provided with a sheath tank, not shown, for supplying sheath liquid to the flow chamber 1321. In the flow chamber 1322, the sample liquid to be measured flows under the sheath liquid, and the small holes 1322 change the sample liquid to be measured into a fine flow, so that particles (formed components) contained in the sample to be measured pass through the small holes 1322 one by one. The electrode 1323 is electrically connected to a dc power supply 1324, and the dc power supply 1324 supplies dc power between the pair of electrodes 1323. During the period when the dc power supply 1324 supplies dc power, the impedance between the pair of electrodes 1323 can be detected. The resistance signal indicating the change in impedance is amplified by the amplifier 1325 and then sent to the control device 150. The magnitude of the resistance signal corresponds to the volume (size) of the particles, so that the red blood cell parameter and the platelet parameter of the sample fluid to be measured can be obtained by signal processing of the resistance signal by the control device 150.

In some embodiments, the detection device 130 further comprises a colorimetric detection portion 133 for detecting a third sample fluid to be detected prepared from a portion of the blood sample to be detected and the hemoglobin reagent supplied from the third reagent supply portion to obtain a hemoglobin parameter.

The display device 140 is used to display information related to blood routine parameters. For example, the display device 140 is configured as a user interface.

In some embodiments, the control device 150 comprises a processor and a storage medium storing a computer program, the control device being configured to perform the following steps when the computer program is executed by the processor: obtaining analysis parameters related to novel coronavirus infection from blood routine parameters of the blood sample to be tested; when the analysis parameters meet the preset conditions, the display device 140 is controlled to display alarm information related to the novel coronavirus infection. Further, the control arrangement 150 is further configured for controlling the display device 140 to display blood parameters of the blood sample to be tested, in particular blood parameters for obtaining analysis parameters related to a novel coronavirus infection. That is, the control device 150 is configured to display alarm information related to a novel coronavirus infection while controlling the display device 140 to display blood routine parameters of the blood sample to be tested.

Alternatively, in other embodiments, the blood analyzer 100 may further include a mode setting device, not shown, for setting a blood routine detection mode or a novel coronavirus infection detection mode. Here, the control device 150 includes a processor and a storage medium storing a computer program, the control device 150 being configured to perform the following steps when the computer program is executed by the processor: when the novel coronavirus infection detection mode is set by the mode setting means, controlling actions of the sampling means 110, the sample preparation 120 and the detection means 130 so as to acquire only analysis parameters related to the novel coronavirus infection; when the blood routine detection mode is set by the mode setting means, the actions of the sampling means 110, the sample preparation 120 and the detection means 130 are controlled to acquire blood routine parameters. That is, the blood analyzer 100 can be selectively operated in either a blood routine detection mode or a novel coronavirus infection detection mode. In the novel coronavirus infection detection mode, the blood analyzer only acquires analysis parameters related to the novel coronavirus infection; in the blood routine test mode, the blood analyzer obtains general blood routine parameters. Further, the control device 150 is configured to control the display device 140 to display alarm information related to the novel coronavirus infection when the analysis parameter satisfies a preset condition. Further, when the blood normative mode is set by the mode setting means, the control means is configured to control the display means 140 to display at least one blood normative parameter. As will be appreciated by those skilled in the art, a routine blood test mode is understood to be a test mode that an existing blood analyzer would have.

In some embodiments, as shown in FIG. 4, the control device 150 includes at least a processing component 151, RAM152, ROM153, a communication interface 154, a memory 156, and an I/O interface 155. The processing component 151, RAM152, ROM153, communication interface 154, memory 156, and I/O interface 155 communicate over bus 157. The processing component may be a CPU, GPU or other chip with computing capabilities. The memory 156 stores various computer programs such as an operating system and application programs for execution by the processor element 151 and data necessary for execution of the computer programs. In addition, during analysis of the blood sample, data stored locally may be stored in memory 156, if desired. The I/O interface 155 is constituted by a serial interface such as USB, IEEE1394, or RS-232C, a parallel interface such as SCSI, IDE, or IEEE1284, and an analog signal interface composed of a D/a converter, an a/D converter, and the like. An input device, such as a keyboard, mouse, touch screen, or other control buttons, is connected to the I/O interface 155, and a user can directly input data to the control device 150 using the input device. In addition, the I/O interface 155 may be connected to a display device 140 having a display function, for example: liquid crystal screens, touch screens, LED display screens, and the like. The control device 150 may output the processed data as image display data to the display device 140 for display, for example: analytical data, instrument operating parameters, etc. The communication interface 154 is an interface that may be any communication protocol known to date. The communication interface 154 communicates with the outside through a network. The control device 150 may communicate data with any device connected via the network via the communication interface 154 in a communication protocol.

In some embodiments, as shown in fig. 1, the blood analyzer 100 further includes a first housing 160 and a second housing 170. The detecting device 130 and the control device 150 are disposed inside the second housing 170, and disposed at both sides of the second housing 170, respectively. The sample preparation device 120 is disposed inside the first housing 160. The display device 140 is disposed on an outer surface of the first casing 160.

In some embodiments, the blood analyzer 100 further comprises a blood sample distribution device (not shown) for dividing the blood sample to be measured drawn by the sampling device 110 into different at least two portions of blood samples for preparing a sample fluid to be measured for measuring different blood parameters. For example, the blood sample distribution device is used for dividing a blood sample to be measured into a first part of blood sample and a second part of blood sample, a first sample liquid to be measured for detecting white blood cells is prepared from the first part of blood sample and white blood cell reagent, a second sample liquid to be measured for detecting red blood cells is prepared from the second part of blood sample and red blood cell reagent, and a third sample liquid to be measured for detecting hemoglobin is optionally prepared from the first part of blood sample or the second part of blood sample and hemoglobin reagent. Alternatively, the blood sample distribution device is configured to divide a blood sample to be measured into a first portion of the blood sample, a second portion of the blood sample, and a third portion of the blood sample, the first sample solution to be measured for detecting white blood cells is prepared from the first portion of the blood sample and a white blood cell reagent, the second sample solution to be measured for detecting red blood cells is prepared from the second portion of the blood sample and a red blood cell reagent, and the third sample solution to be measured for detecting hemoglobin is prepared from the third portion of the blood sample and a hemoglobin reagent. The blood sample distribution device may be configured, for example, as a blood separation valve. Alternatively, the blood sample dispensing device may be a sampling needle of the sampling device 110, in which case the driving part of the sampling device 110 drives the sampling needle to move to the position of different reaction cells of the sample preparation device 120 to dispense a portion of the blood sample to be tested into the different reaction cells to react with the corresponding processing reagent, respectively.

In some embodiments, the analysis parameters include at least two blood convention parameters, or a combination parameter including at least two blood convention parameters, such as a linear or non-linear combination parameter. In these embodiments, the control device 150 controls the display device 140 to display alarm information related to the novel coronavirus infection when at least two blood routine parameters respectively satisfy the respective predetermined conditions or one parameter combined by the at least two blood routine parameters satisfies the predetermined conditions.

In some embodiments, the analysis parameter comprises at least one of a leukocyte parameter, a erythrocyte parameter, a platelet parameter, and a hemoglobin parameter, for example, the analysis parameter comprises at least one leukocyte parameter or at least one erythrocyte parameter or at least one platelet parameter or at least one hemoglobin parameter.

In some embodiments, the analysis parameters include a combination of a plurality of parameters selected from the group consisting of a leukocyte parameter, a erythrocyte parameter, a platelet parameter, and a hemoglobin parameter. For example, the analysis parameters include a combination of a plurality of leukocyte parameters or a combination of a plurality of erythrocyte parameters or a combination of a plurality of platelet parameters. For example, the analysis parameters include a combination of at least one leukocyte parameter and at least one erythrocyte parameter or a combination of at least one leukocyte parameter and at least one platelet parameter or a combination of at least one erythrocyte parameter and at least one platelet parameter or a combination of at least one leukocyte parameter, at least one erythrocyte parameter and at least one platelet parameter.

Further, the analysis parameters include at least one of the following blood routine parameters or a combination of a plurality of the following blood routine parameters, such as a linear or non-linear combination parameter: white blood cell count, neutrophil number, neutrophil percentage, lymphocyte number, lymphocyte percentage, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, red blood cell distribution width coefficient of variation, red blood cell distribution width standard deviation, red blood cell number, large red blood cell ratio, small red blood cell ratio, platelet distribution width standard deviation, average platelet volume, large platelet ratio, high fluorescence intensity cell percentage, average red blood cell hemoglobin concentration, hemoglobin concentration.

Preferably, the analysis parameters include at least one of the following blood routine parameters and a combination of a plurality of the following blood routine parameters: neutrophil to lymphocyte ratio, lymphocyte percentage, erythrocyte distribution width variation coefficient, erythrocyte distribution width standard deviation, and high fluorescence intensity cell percentage.

The inventor finds that the parameters related to the distribution width of the red blood cells have better alarm efficacy for alarming the novel coronavirus infection sample in the process of researching the blood routine parameters of a large number of novel coronavirus infection samples. Thus, in some embodiments, the analysis parameter comprises at least one red blood cell distribution width parameter, in particular comprises a red blood cell distribution width coefficient of variation or a red blood cell distribution width standard deviation, or comprises a red blood cell distribution width coefficient of variation and a red blood cell distribution width standard deviation. In some embodiments, the analysis parameters include a combination of at least one red blood cell distribution width parameter and at least one additional blood convention parameter, including, for example, a neutrophil to lymphocyte ratio, a lymphocyte percentage, or a high fluorescence intensity cell percentage. Therefore, the alarm of the novel coronavirus infection sample by utilizing the distribution width parameter of the red blood cells can be realized.

The inventors found that in studying the blood normative parameters of a large number of novel coronavirus infection samples, it is particularly advantageous to alarm the novel coronavirus infection samples by combining the neutrophil to lymphocyte ratio with other blood normative parameters. Thus, preferably, the analysis parameters comprise a combination of neutrophil to lymphocyte ratios and at least one further blood convention parameter. The at least one further blood conventional parameter comprises, for example, at least one red blood cell parameter, in particular a red blood cell distribution width parameter (e.g. a red blood cell distribution width coefficient of variation or a red blood cell distribution width standard deviation).

In some embodiments, the alarm information related to a novel coronavirus infection includes alarm information for prompting the blood sample to be tested to be a positive sample of a novel coronavirus infection. For example, when the analysis parameter meets a first preset condition, alarm information for prompting that the blood sample to be tested is a novel coronavirus infection positive sample is displayed on a display device of the blood analyzer. In these embodiments, the blood sample to be tested may be a blood sample of a patient suspected of being infected with a novel coronavirus.

In the case that the blood analyzer provided by the embodiment of the invention is used for outputting the alarm information for prompting the blood sample to be tested to be a novel coronavirus infection positive sample, it is particularly advantageous that the analysis parameters comprise at least one blood routine parameter of the following blood routine parameters or a combination of a plurality of blood routine parameters of the following blood routine parameters, such as a linear or nonlinear combination parameter: white blood cell count, percent lymphocytes, neutrophil to lymphocyte ratio, and red blood cell distribution width parameter (e.g., red blood cell distribution width coefficient of variation). Of course, the analysis parameters may also include at least one of the above blood routine parameters and a combination of a plurality of the above blood routine parameters. Preferably, the analysis parameters comprise a red blood cell distribution width parameter, in particular a red blood cell distribution width coefficient of variation. In some embodiments, the analysis parameters may also include a combination of neutrophil to lymphocyte ratio and a red blood cell distribution width parameter, particularly a coefficient of variation of the red blood cell distribution width.

As shown in fig. 6 to 8, the inventors studied the efficacy of a novel coronavirus infection positive alarm on 318 blood samples using one or a combination of parameters of white blood cell count WBC, lymphocyte percentage LYM, neutrophil to lymphocyte ratio NLR, red blood cell distribution width variation coefficient rdw_cv, wherein 156 novel coronavirus infection positive samples and 162 negative samples. Fig. 6 is a ROC curve of novel coronavirus infection positive alarm by using white blood cell count WBC, lymphocyte percentage LYM, neutrophil to lymphocyte ratio NLR, erythrocyte distribution width variation coefficient rdw_cv, respectively, and as can be seen from fig. 6, the alarm efficacy by using erythrocyte distribution width variation coefficient rdw_cv alone is auc=0.78, the specificity is 63%, the sensitivity is 78.8%, and the effect is better. Fig. 7 shows ROC curves for novel coronavirus infection positive alarms using linear combinations of WBC and LYM% and linear combinations of NLR and rdw_cv, as can be seen from fig. 7, AUC for linear combination parameters of NLR and rdw_cv (linear combination formula e.g., 0.0585 x NLR-0.352 x rdw_cv+4.6641) can reach 0.83 (specificity of 69.1%, sensitivity of 80.1%) significantly better than the combination of parameters of WBC and LYM% (AUC of 0.71, specificity of 67.3%, sensitivity of 63.5%). FIG. 8 is a ROC curve for novel coronavirus infection positive alarms using a nonlinear combination of NLR and RDW_CV, wherein AUC is 0.82, specificity is 71.6%, sensitivity is 72.4%, and the nonlinear combination formula of NLR and RDW_CV is as follows:

-0.3332*NLR+46.1415*RDW_CV+0.0186NLR.^2+0.0165*NLR*RDW_CV-1.8844*RDW_CV.^2-281.615。

In the embodiment of the invention, a method of linear discriminant analysis LDA (Linear Discriminant Analysis) is selected for linear combination analysis, and QDA (Quadratic discriminant analysis) is selected for nonlinear combination analysis.

Because of the different degree of infection, some blood routine parameters of patients with new coronaries have different numerical characteristics, such as normal or decreased total white blood cells, decreased lymphocyte counts, etc., in early stages of onset. Thus, in some embodiments, the alarm information related to a novel coronavirus infection comprises alarm information for alerting the blood sample to be tested to the extent of the novel coronavirus infection. For example, when the analysis parameter meets a second preset condition, alarm information for prompting the novel coronavirus infection degree of the blood sample to be tested is displayed on a display device of the blood analyzer. The extent of the novel coronavirus infection includes both minor and severe. That is, the blood analyzer provided by the embodiment of the invention can not only alarm whether the blood sample is a novel coronavirus positive sample, but also further alarm the infection degree of the novel coronavirus positive sample. In this case, the blood sample to be tested is preferably a blood sample of a patient infected with a novel coronavirus.

Advantageously, the analysis parameters include at least one of the following blood routine parameters or a combination of a plurality of the following blood routine parameters, for example a linear or a nonlinear combination parameter: white blood cell count, percent lymphocytes, percent neutrophils, platelet to lymphocyte ratio, red blood cell distribution width parameter (e.g., standard deviation of red blood cell distribution width), red blood cell number. Of course, the analysis parameters may also include at least one of the above blood routine parameters and a combination of a plurality of the above blood routine parameters. Preferably, the analytical parameter comprises lymphocyte percentage. Further preferably, the analysis parameters comprise a combination parameter, in particular a linear combination parameter, of lymphocyte percentages and of red blood cell distribution width parameters, in particular of standard deviations of red blood cell distribution width. In some embodiments, the analysis parameters may also include a combination of neutrophil to lymphocyte ratio and red blood cell number, especially a nonlinear combination.

As shown in fig. 9 to 11, the inventors studied the efficacy of warning the novel coronavirus infection degree of 239 cases of novel coronavirus infection positive samples by using one parameter or a combination of parameters of white blood cell count WBC, lymphocyte percentage LYM, neutrophil percentage Neu, platelet to lymphocyte ratio PLR, red blood cell distribution width standard deviation rdw_sd, and red blood cell number RBC, wherein 108 cases of severe cases and 131 cases of mild cases of cases. Fig. 9 is a ROC curve of the novel coronavirus infection level alarm using white blood cell count WBC, lymphocyte percentage LYM%, platelet to lymphocyte ratio PLR and red blood cell distribution width standard deviation rdw_sd, respectively, and as can be seen from fig. 9, the alarm efficacy using lymphocyte percentage LYM% alone is auc=0.84, with better effect. Fig. 10 is a ROC curve for novel coronavirus infection level alerting using a linear combination of LYM% and rdw_sd, wherein auc=0.9, and the linear combination formula of LYM% and rdw_sd is, for example, -0.0857 x LYM% +0.1337 x rdw_sd-3.5294. Fig. 11 is a ROC curve for novel coronavirus infection level alerting using a nonlinear combination of Neu% and RBC, where auc=0.85, and the nonlinear combination formula of Neu% and RBC is, for example:

0.5705*Neu%-9.1627*RBC-0.0037*Neu%.^2+0.039*Neu%*RBC+0.6265*RBC.^2-7.9552。

In some embodiments, the alarm information related to a novel coronavirus infection comprises alarm information for alerting the blood sample to be tested to a trend of the novel coronavirus infection. For example, when the analysis parameter satisfies a third preset condition, alarm information for prompting the development trend of the novel coronavirus infection of the blood sample to be tested is displayed on a display device of the blood analyzer. That is, the blood sample analyzer provided by the embodiment of the invention can also assist medical staff in predicting the disease course of a patient diagnosed with a novel coronavirus, i.e. can give an alarm for the prognosis of the infection with the novel coronavirus. In the embodiment of the invention, bad prognosis means that the ill animals possibly die or cannot be thoroughly cured due to critical illness state or no effective treatment method yet, and the production performance or economic value is influenced; the good prognosis means that the disease condition is light, the individual condition of the diseased animal is good, the disease can be cured according to sufficient basis, the health can be recovered, and the production performance and the economic value are not influenced. In this case, the blood sample to be tested is preferably a blood sample of a patient infected with a novel coronavirus.

In the case where the blood analyzer provided by the embodiments of the present invention is used for alerting a prognosis of a novel coronavirus infection, it is particularly advantageous that the analysis parameters include at least one of the following blood routine parameters or a combination of a plurality of the following blood routine parameters: red blood cell distribution width parameters (e.g., red blood cell distribution width standard deviation), large red blood cell ratio, small red blood cell ratio, platelet to lymphocyte ratio, platelet distribution width parameters (e.g., platelet distribution width and platelet distribution width standard deviation), large platelet ratio, average platelet volume, high fluorescence intensity cell percentage, average red blood cell hemoglobin concentration. Preferably, the analysis parameter comprises a large platelet ratio. In some embodiments, the analysis parameters include a combination parameter, in particular a linear combination parameter, of a high fluorescence intensity cell percentage and a red blood cell distribution width parameter, in particular a red blood cell distribution width standard deviation. In some embodiments, the analysis parameters include a combination parameter, particularly a linear combination parameter, of a large red blood cell ratio, an average platelet volume, and an average red blood cell hemoglobin concentration. In yet other embodiments, the analysis parameters include a combination parameter, in particular a nonlinear combination parameter, of the small red blood cell ratio and the platelet distribution width parameter, in particular the platelet distribution width standard deviation.

As shown in fig. 12 to 15, the inventors studied the efficacy of prognosis alarm for 52 novel coronavirus infection positive samples using one or a combination of parameters of red cell distribution width standard deviation rdw_sd, large red cell ratio MacroRBC, small red cell ratio MicroRBC, platelet to lymphocyte ratio PLR, platelet distribution width PDW, platelet distribution width standard deviation pdw_sd, large platelet ratio p_lcr, average platelet volume MPV, high fluorescence intensity cell percentage HFC, average red cell hemoglobin concentration MCHC, among them, poor prognosis samples 23 cases, good prognosis samples 29 cases. Fig. 12 is a ROC curve of a novel coronavirus infection prognosis alarm using the platelet-to-lymphocyte ratio PLR, the platelet distribution width PDW, the large platelet ratio p_lcr, and the high fluorescence intensity cell percentage HFC% alone, respectively, as can be seen from fig. 12, the alarm efficacy using the large platelet ratio p_lcr alone is auc=0.83, with a better effect. Fig. 13 is a ROC curve for novel coronavirus infection prognostic alerting using a linear combination of HFC% and rdw_sd, wherein AUC = 0.83, and the combined formula of HFC% and rdw_sd is, for example, 2.2388 x HFC% +0.4138 x rdw_sd-6.1972. Fig. 14 is a ROC curve for novel coronavirus infection prognostic alerting using a linear combination of MCHC, macroRBC% and MPV, wherein AUC = 0.86, the combined formula of mchc, macroRBC% and MPV is, for example, -0.0374 x mchc-0.4008 x MacroRBC% +0.8149 x mpv+5.8068. Fig. 15 is a ROC curve for novel coronavirus infection prognostic alerting using a nonlinear combination of MicroRBC% and pdw_sd, where AUC = 0.85, the nonlinear combination formula of MicroRBC% and pdw_sd is, for example:

0.1303*MicroRBC%-4.69*PDW_SD-0.2429*MicroRBC%.^2+0.1432*MicroRBC%*PDW_SD+0.2166*PDW_SD.^2+22.3023。

The embodiment of the invention also provides a blood analysis method for alarming a new coronavirus infection sample according to blood routine parameters, as shown in fig. 16, the blood analysis method 200 comprises the following steps:

s210, providing a blood analyzer;

s220, sucking a blood sample to be tested by a sampling and distributing device of the blood analyzer;

s230, mixing a part of the blood sample to be tested with a treatment reagent in at least one reaction tank of a blood analyzer to prepare a sample solution to be tested;

s240, detecting blood cells in the sample liquid to be detected in a detection device of a blood analyzer to obtain blood routine parameters;

s250, acquiring analysis parameters related to novel coronavirus infection from blood routine parameters of the blood sample to be tested;

and S260, displaying information related to the novel coronavirus infection on a display device of the blood analyzer when the analysis parameters meet preset conditions.

In some embodiments, after the blood sample sucking step S220 and before the preparing step S230 of the sample liquid to be tested, the method further includes: the sample distribution device divides the blood sample to be measured into at least two parts. For example, the sample distribution device divides the blood sample to be measured into a first portion of the blood sample, a second portion of the blood sample, and optionally a third portion of the blood sample.

Here, the step S230 of preparing the sample liquid to be measured includes: mixing the first portion of blood sample with a leukocyte reagent to prepare a first sample fluid to be tested for detecting a leukocyte parameter; mixing the second partial blood sample with a red blood cell reagent to prepare a second sample solution to be tested for detecting red blood cell parameters; mixing the first, second or third portion of blood sample with a hemoglobin reagent to prepare a third sample fluid to be tested for detecting a hemoglobin parameter. That is, the third sample liquid to be measured and the first sample liquid to be measured may be prepared using the same portion of the blood sample, or the third sample liquid to be measured and the second sample liquid to be measured may be prepared using the same portion of the blood sample, or the first, second, and third sample liquids may be prepared using different portions of the blood sample, respectively.

Here, the blood routine parameter detection step S240 includes: detecting the first sample liquid to be detected in an optical detection part of the blood analyzer to obtain white blood cell parameters, and optionally also obtaining platelet parameters; detecting the second sample liquid to be detected in an impedance detection part of the blood analyzer to obtain red blood cell parameters and platelet parameters; the third sample liquid to be measured is detected in a colorimetric detection portion of the blood analyzer to obtain a hemoglobin parameter.

In some embodiments, the step of obtaining the leukocyte parameters comprises: white blood cells in the first sample fluid to be tested are counted and classified in an optical detection section of a hematology analyzer. For example, the leukocyte parameters include at least leukocyte count, neutrophil number and ratio, lymphocyte number and ratio, monocyte number and ratio.

Other embodiments of the blood analysis method 200 provided by the present invention may refer to the above description of the blood analyzer 100 provided by the embodiments of the present invention, and will not be repeated here.

An embodiment of the present invention also provides a computer-readable storage medium applied to a blood analyzer, the computer-readable storage medium storing a computer program, wherein the computer program when executed by a processor implements the steps of: obtaining blood routine parameters of a blood sample to be tested, which are measured by a detection device of a blood analyzer; obtaining analysis parameters related to novel coronavirus infection from blood routine parameters of the blood sample to be tested; and when the analysis parameters meet preset conditions, indicating to display information related to the novel coronavirus infection on a display device of the blood analyzer.

Other embodiments of the computer readable storage medium provided by the present invention may refer to the above description of the blood analyzer 100 and the blood analysis method 200 provided by the embodiments of the present invention, and are not repeated here.

Individual features or combinations of features described in the individual embodiments of the description, the drawing and the claims can be combined with one another in any desired manner, insofar as they are of significance and do not contradict one another within the scope of the embodiments of the invention. The details, features and advantages described for the blood analyzer 100 provided with respect to the embodiments of the present invention apply in a corresponding manner to the blood analysis method 200 and the computer readable storage medium provided with respect to the embodiments of the present invention, and vice versa.

The foregoing is only a specific embodiment of the invention to enable those skilled in the art to understand or practice the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A blood analyzer, comprising:

a sampling device having a pipette with a pipette nozzle and having a driving section for driving the pipette to quantitatively aspirate a blood sample to be measured through the pipette nozzle;

a sample preparation device having at least one reaction cell for receiving a blood sample to be measured sucked by the sampling device and a reagent supply section for supplying a processing reagent to the at least one reaction cell so that the blood sample to be measured sucked by the sampling device and the processing reagent supplied by the reagent supply section are mixed in the reaction cell to prepare a sample liquid to be measured;

a detection device for detecting the sample liquid to be detected prepared by the sample preparation device to obtain blood routine parameters;

display means for displaying information related to blood routine parameters; and

control apparatus comprising a processor and a storage medium storing a computer program, wherein the control apparatus is configured to perform the following steps when the computer program is executed by the processor:

obtaining analysis parameters related to novel coronavirus infection from blood routine parameters of the blood sample to be tested, wherein the analysis parameters comprise at least one of red blood cell parameters, platelet parameters and hemoglobin parameters, or a combination of a plurality of parameters selected from the group consisting of red blood cell parameters, platelet parameters and hemoglobin parameters;

2. A blood analyzer, comprising:

display means for displaying information related to blood routine parameters;

a mode setting device for setting a blood routine detection mode or a novel coronavirus infection detection mode; and

controlling actions of the sampling device, the sample preparation and the detection device when a novel coronavirus infection detection mode is set by the mode setting device so as to obtain only analysis parameters related to novel coronavirus infection among blood routine parameters of the blood sample to be tested, wherein the analysis parameters comprise at least one parameter of erythrocyte parameters, platelet parameters and hemoglobin parameters, or a combination parameter of a plurality of parameters selected from among erythrocyte parameters, platelet parameters and hemoglobin parameters;

3. The blood analyzer of claim 1 or 2, wherein the analysis parameters comprise at least two blood normative parameters or the analysis parameters comprise a combination of at least two blood normative parameters.

4. The blood analyzer according to claim 1 or 2, wherein the reagent supply section includes a first reagent supply section for supplying a leukocyte reagent, a second reagent supply section for supplying an erythrocyte reagent, and a third reagent supply section for supplying a hemoglobin reagent;

The detection device includes:

an optical detection section for detecting a first sample liquid to be measured prepared from a part of the blood sample to be measured and a leukocyte reagent supplied from the first reagent supply section to obtain a leukocyte parameter and optionally a platelet parameter,

an impedance detecting section for detecting a second sample liquid to be measured prepared from a part of the blood sample to be measured and the red blood cell reagent supplied from the second reagent supplying section to obtain a red blood cell parameter and a platelet parameter,

a colorimetric detection section for detecting a third sample liquid to be measured prepared from a part of the blood sample to be measured and a hemoglobin reagent supplied from the third reagent supply section to obtain a hemoglobin parameter;

wherein the analysis parameters further comprise a combination of at least one leukocyte parameter and at least one parameter selected from the group consisting of a erythrocyte parameter, a platelet parameter, and a hemoglobin parameter.

5. The blood analyzer according to claim 1 or 2, wherein the analysis parameters comprise at least one of the following blood routine parameters and/or a combination of a plurality of the following blood routine parameters:

Platelet to lymphocyte ratio, red cell distribution width coefficient of variation, red cell distribution width standard deviation, red cell number, large red cell ratio, small red cell ratio, platelet distribution width standard deviation, average platelet volume, large platelet ratio, high fluorescence intensity cell percentage, average red cell hemoglobin concentration;

or alternatively

The analysis parameters include a combination of at least one blood convention parameter of white blood cell count, neutrophil percentage, lymphocyte percentage, neutrophil to lymphocyte ratio and at least one blood convention parameter of platelet to lymphocyte ratio, coefficient of variation of distribution width of red blood cells, standard deviation of distribution width of red blood cells, number of red blood cells, proportion of big red blood cells, proportion of small red blood cells, standard deviation of distribution width of platelets, average platelet volume, big platelet ratio, percentage of high fluorescence intensity cells, average concentration of red blood cells and hemoglobin.

6. The blood analyzer according to claim 1 or 2, wherein the analysis parameters comprise at least one red blood cell distribution width parameter or the analysis parameters comprise a combination of at least one red blood cell distribution width parameter and at least one further blood routine parameter;

Wherein the red blood cell distribution width parameter comprises a red blood cell distribution width variation coefficient and/or a red blood cell distribution width standard deviation.

7. The blood analyzer according to claim 1 or 2, wherein the alarm information related to the novel coronavirus infection includes alarm information for prompting the blood sample to be tested to be a positive sample of the novel coronavirus infection.

8. The blood analyzer of claim 7, wherein the analysis parameters include a coefficient of variation of a distribution width of red blood cells; and/or

The analysis parameters include a combination of at least one of white blood cell count, lymphocyte percentage, neutrophil to lymphocyte ratio and erythrocyte distribution width coefficient of variation.

9. The blood analyzer according to claim 1 or 2, wherein the alarm information related to the novel coronavirus infection includes alarm information for prompting the degree of the novel coronavirus infection of the blood sample to be measured.

10. The blood analyzer of claim 9, wherein the analysis parameters include at least one of the following blood routine parameters and/or a combination of a plurality of the following blood routine parameters: platelet to lymphocyte ratio, standard deviation of red blood cell distribution width, and red blood cell number; and/or

The analysis parameters comprise at least one blood routine parameter of white blood cell count, lymphocyte percentage, neutrophil percentage, and at least one blood routine parameter of platelet-to-lymphocyte ratio, standard deviation of red blood cell distribution width, and red blood cell number.

11. The hematology analyzer of claim 10, wherein the analysis parameters include a combination of lymphocyte percentages and standard deviations of red blood cell distribution widths; and/or

The analytical parameters include a combination of neutrophil percentage and red blood cell number.

12. The blood analyzer according to claim 1 or 2, wherein the alarm information related to the novel coronavirus infection includes alarm information for prompting the development trend of the novel coronavirus infection of the blood sample to be measured.

13. The blood analyzer of claim 12, wherein the analysis parameters include at least one of the following blood routine parameters and/or a combination of a plurality of the following blood routine parameters: the standard deviation of the distribution width of the red blood cells, the proportion of the big red blood cells, the proportion of the small red blood cells, the ratio of the platelets to the lymphocytes, the distribution width of the platelets, the standard deviation of the distribution width of the platelets, the proportion of the big platelets, the average platelet volume, the percentage of the cells with high fluorescence intensity and the average concentration of the red blood cells and the hemoglobin.

14. The blood analyzer of claim 13, wherein the analysis parameters include a large platelet ratio; and/or

The analysis parameters comprise combination parameters of high fluorescence intensity cell percentage and red blood cell distribution width standard deviation; and/or

The analysis parameters comprise a combination of a large red blood cell proportion, an average platelet volume and an average red blood cell hemoglobin concentration; and/or

The analysis parameters include a combination of parameters of small red blood cell ratio and standard deviation of platelet distribution width.

15. The blood analyzer of claim 10, wherein the blood sample to be tested is derived from a patient infected with a novel coronavirus.

16. The blood analyzer according to claim 1 or 2, wherein the control device is configured to perform the following steps when the computer program is executed by the processor:

and controlling the display device to display the blood routine parameters of the blood sample to be tested.

17. A computer readable storage medium for use in a blood analyzer, the computer readable storage medium having a computer program stored thereon, the computer program when executed by a processor performing the steps of:

Obtaining blood routine parameters of a blood sample to be tested, which are measured by a detection device of a blood analyzer;

and when the analysis parameters meet preset conditions, indicating to display information related to the novel coronavirus infection on a display device of the blood analyzer.